

MARKET REPORT



Acne Vulgaris (AV)- Market Insight, Epidemiology and Market Forecast - 2027

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Acne Vulgaris (AV)- Market Insight, Epidemiology and Market Forecast - 2027

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Acne Vulgaris (AV)- Market Insight, Epidemiology and Market Forecast - 2027

DelveInsight's "Acne Vulgaris (AV) - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Acne Vulgaris (AV) epidemiology and market outlook for the 7MM.

Markets Covered

- United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan

Study Period: 2016-2027

Acne Vulgaris (AV) Understanding and Treatment Algorithm

The market report provides the overview of the Acne Vulgaris (AV) by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

Acne Vulgaris (AV) Epidemiology

The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Acne Vulgaris (AV) in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

Acne Vulgaris (AV) Product Profiles & Analysis

The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

Acne Vulgaris (AV) Market Outlook

The report's market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Acne Vulgaris (AV) market.

Acne Vulgaris (AV) Market Share by Therapies

This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

Acne Vulgaris (AV) Report Insights

- Patient Population in Acne Vulgaris (AV)
- Therapeutic Approaches in Acne Vulgaris (AV)
- Acne Vulgaris (AV) Pipeline Analysis
- Acne Vulgaris (AV) Market Size and Trends
- Acne Vulgaris (AV) Market Opportunities
- Impact of upcoming Therapies in Acne Vulgaris (AV)

Acne Vulgaris (AV) Report Key Strengths

- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition

Acne Vulgaris (AV) Report Assessment

- Current Treatment Practices in Acne Vulgaris (AV)
- Unmet Needs in Acne Vulgaris (AV)
- Market Attractiveness
- Market Drivers and Barriers

Key Benefits

- The report will help to develop Business Strategies by understanding the trends shaping and driving the Acne Vulgaris (AV) market
- Organize sales and marketing efforts by identifying the best opportunities for Acne Vulgaris (AV) market
- To understand the future market competition in the Acne Vulgaris (AV) market.

Additional Details

Publisher : Delve Insight

Reference : DIMI0008
Number of Pages : 100
Report Format : PDF
Publisher Information :



DELVEINSIGHT
INSIGHTS. EXPERTISE. ACTIONABLE DATA.

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Table Of Contents for Acne Vulgaris (AV)- Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

- 1. Report Introduction
- 2. Acne Vulgaris (AV) Market Overview at a Glance
 - 2.1. Market Share Distribution of Acne Vulgaris (AV) in 2017
 - 2.2. Market Share Distribution of Acne Vulgaris (AV) in 2027
- 3. Disease Background and Overview: Acne Vulgaris (AV)
 - 3.1. Introduction
 - 3.2. Symptoms
 - 3.3. Etiology
 - 3.4. Risk Factors
 - 3.5. Pathophysiology
 - 3.6. Diagnosis
 - 3.7. Treatment
- 4. Epidemiology and Patient Population
 - 4.1. Key Findings
 - 4.2. Total Prevalent/ Incident Patient Population of Acne Vulgaris (AV) in 7MM
 - 4.3. Total Prevalent Patient Population of Acne Vulgaris (AV) in 7MM - By Countries
- 5. Epidemiology of Acne Vulgaris (AV) by Countries
 - 5.1. United States
 - 5.1.1. Assumptions and Rationale
 - 5.1.2. Prevalent/Incident Cases of the Acne Vulgaris (AV)
 - 5.1.3. Sub-Type Specific cases of the Acne Vulgaris (AV) *5.1.4. Sex- Specific Cases of the Acne Vulgaris (AV)*5.1.5. Diagnosed Cases of the Acne Vulgaris (AV)
 - 5.1.6. Treatable Cases of the Acne Vulgaris (AV)
 - 5.2. EU
 - 5.3. Assumptions and Rationale
 - 5.4. Germany
 - 5.4.1. Assumptions and Rationale
 - 5.4.2. Prevalent/Incident Cases of the Acne Vulgaris (AV)
 - 5.4.3. Sub-Type Specific cases of the Acne Vulgaris (AV)*5.4.4. Sex- Specific Cases of the Acne Vulgaris (AV)*5.4.5. Diagnosed Cases of the Acne Vulgaris (AV)
 - 5.4.6. Treatable Cases of the Acne Vulgaris (AV)
 - 5.5. France
 - 5.5.1. Assumptions and Rationale
 - 5.5.2. Prevalent/Incident Cases of the Acne Vulgaris (AV)
 - 5.5.3. Sub-Type Specific cases of the Acne Vulgaris (AV)*5.5.4. Sex- Specific Cases of the Acne Vulgaris (AV)*5.5.5. Diagnosed Cases of the Acne Vulgaris (AV)
 - 5.5.6. Treatable Cases of the Acne Vulgaris (AV)
 - 5.6. Italy
 - 5.6.1. Assumptions and Rationale
 - 5.6.2. Prevalent/Incident Cases of the Acne Vulgaris (AV)
 - 5.6.3. Sub-Type Specific cases of the Acne Vulgaris (AV)*5.6.4. Sex- Specific Cases of the Acne Vulgaris (AV)*5.6.5. Diagnosed Cases of the Acne Vulgaris (AV)
 - 5.6.6. Treatable Cases of the Acne Vulgaris (AV)
 - 5.7. Spain
 - 5.7.1. Assumptions and Rationale
 - 5.7.2. Prevalent/Incident Cases of the Acne Vulgaris (AV)
 - 5.7.3. Sub-Type Specific cases of the Acne Vulgaris (AV)*5.7.4. Sex- Specific Cases of the Acne Vulgaris (AV)*5.7.5. Diagnosed Cases of the Acne Vulgaris (AV)
 - 5.7.6. Treatable Cases of the Acne Vulgaris (AV)
 - 5.8. United Kingdom
 - 5.8.1. Assumptions and Rationale
 - 5.8.2. Prevalent/Incident Cases of the Acne Vulgaris (AV)
 - 5.8.3. Sub-Type Specific cases of the Acne Vulgaris (AV)*5.8.4. Sex- Specific Cases of the Acne Vulgaris (AV)*5.8.5. Diagnosed Cases of the Acne Vulgaris (AV)
 - 5.8.6. Treatable Cases of the Acne Vulgaris (AV)
 - 5.9. Japan
 - 5.9.1. Assumptions and Rationale
 - 5.9.2. Prevalent/Incident Cases of the Acne Vulgaris (AV)
 - 5.9.3. Sub-Type Specific cases of the Acne Vulgaris (AV)*5.9.4. Sex- Specific Cases of the Acne Vulgaris (AV)*5.9.5. Diagnosed Cases of the Acne Vulgaris (AV)
 - 5.9.6. Treatable Cases of the Acne Vulgaris (AV)
 - 6. Current Treatment & Medical practices
 - 6.1. Treatment Algorithm
 - 6.2. Treatment Guidelines
 - 7. Unmet Needs of the Acne Vulgaris (AV)
 - 8. Marketed Therapies
 - 8.1. Drug A: Company 18
 - 8.1.1. Drug Description
 - 8.1.2. Mechanism of Action
 - 8.1.3. Regulatory Milestones
 - 8.1.4. Advantages & Disadvantages
 - 8.1.5. Product Profile
 - 8.2. Drug B: Company 28
 - 8.2.1. Drug Description
 - 8.2.2. Mechanism of Action
 - 8.2.3. Regulatory Milestones
 - 8.2.4. Advantages & Disadvantages
 - 8.2.5. Product Profile
 - 9. Pipeline Therapies - At a glance
 - 10. Key Cross Competition
 - 11. Emerging Therapies for Acne Vulgaris (AV)
 - 11.1. Drug C: Company 311
 - 11.1.1. Drug Description
 - 11.1.2. Clinical Trials Details
 - 11.1.3. Safety and Efficacy Profile
 - 11.1.4. Advantages & Disadvantages
 - 11.1.5. Pipeline Development Activities
 - 11.1.6. Product Profile
 - 11.2. Drug D: Company 411
 - 11.2.1. Drug Description
 - 11.2.2. Clinical Trials Details
 - 11.2.3. Safety and Efficacy Profile
 - 11.2.4. Advantages & Disadvantages
 - 11.2.5. Pipeline Development Activities
 - 11.2.6. Product Profile
 - 12. Acne Vulgaris (AV): 7MM Market Analysis
 - 12.1. 7MM Market Size of Acne Vulgaris (AV)
 - 12.2. 7MM Percentage Share of drugs marketed for Acne Vulgaris (AV)
 - 12.3. 7MM Market Sales of Acne Vulgaris (AV) by Products
 - 13. Acne Vulgaris (AV): Country-Wise Market Analysis
 - 13.1. United States
 - 13.1.1. Market Size of Acne Vulgaris (AV) in United States
 - 13.1.2. Percentage Share of drugs marketed for Acne Vulgaris (AV) in United States
 - 13.1.3. Market Sales of Acne Vulgaris (AV) by Products in United States
 - 13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
 - 13.2. EU-5
 - 13.2.1. Germany
 - 13.2.1.1. Market Size of Acne Vulgaris (AV) in Germany
 - 13.2.1.2. Percentage Share of drugs marketed for Acne Vulgaris (AV) in Germany
 - 13.2.1.3. Market Sales of Acne Vulgaris (AV) by Products in Germany
 - 13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
 - 13.2.2. France
 - 13.2.2.1. Market Size of Acne Vulgaris (AV) in France
 - 13.2.2.2. Percentage Share of drugs marketed for Acne Vulgaris (AV) in France
 - 13.2.2.3. Market Sales of Acne Vulgaris (AV) by Products in France
 - 13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
 - 13.2.3. Italy
 - 13.2.3.1. Market Size of Acne Vulgaris (AV) in Italy
 - 13.2.3.2. Percentage Share of drugs marketed for Acne Vulgaris (AV) in Italy
 - 13.2.3.3. Market Sales of Acne Vulgaris (AV) by Products in Italy
 - 13.2.3.4. Analysis of Upcoming Therapies and their

Impact on the Market13.2.4. Spain13.2.4.1. Market Size of Acne Vulgaris (AV) in Spain13.2.4.2. Percentage Share of drugs marketed for Acne Vulgaris (AV) in Spain13.2.4.3. Market Sales of Acne Vulgaris (AV) by Products in Spain13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market13.2.5. United Kingdom13.2.5.1. Market Size of Acne Vulgaris (AV) in United Kingdom13.2.5.2. Percentage Share of drugs marketed for Acne Vulgaris (AV) in United Kingdom13.2.5.3. Market Sales of Acne Vulgaris (AV) by Products in United Kingdom13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market13.3. Japan13.3.1. Market Size of Acne Vulgaris (AV) in Japan13.3.2. Percentage Share of drugs marketed for Acne Vulgaris (AV) in Japan13.3.3. Market Sales of Acne Vulgaris (AV) by Products in Japan13.3.4. Analysis of Upcoming Therapies and their Impact on the Market14. Market Drivers15. Market Barriers16. Appendix17. Report Methodology17.1. Sources18. DelveInsight Capabilities19. Disclaimer20. About DelveInsight*Indication Specific

List Of Tables in Acne Vulgaris (AV)- Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Acne Vulgaris (AV) in 7MM

Table 2: Total Prevalent/Incident Cases of the Acne Vulgaris (AV) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Acne Vulgaris (AV) in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Acne Vulgaris (AV) in United States (2016-2027)

Table 5: Sex- Specific Cases of the Acne Vulgaris (AV) in United States (2016-2027)

Table 6: Diagnosed Cases of the Acne Vulgaris (AV) in United States (2016-2027)

Table 7: Treatable Cases of the Acne Vulgaris (AV) in United States (2016-2027)

Table 8: Prevalent/Incident Cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Table 9: Sub-Type Specific cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Table 10: Sex- Specific Cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Table 11: Diagnosed Cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Table 12: Treatable Cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Table 13: Prevalent/Incident Cases of the Acne Vulgaris (AV) in France (2016-2027)

Table 14: Sub-Type Specific cases of the Acne Vulgaris (AV) in France (2016-2027)

Table 15: Sex- Specific Cases of the Acne Vulgaris (AV) in France (2016-2027)

Table 16: Diagnosed Cases of the Acne Vulgaris (AV) in France (2016-2027)

Table 17: Treatable Cases of the Acne Vulgaris (AV) in France (2016-2027)

Table 18: Prevalent/Incident Cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Table 19: Sub-Type Specific cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Table 20: Sex- Specific Cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Table 21: Diagnosed Cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Table 22: Treatable Cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Table 23: Prevalent/Incident Cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Table 24: Sub-Type Specific cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Table 25: Sex- Specific Cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Table 26: Diagnosed Cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Table 27: Treatable Cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Table 28: Prevalent/Incident Cases of the Acne Vulgaris (AV) in UK (2016-2027)

Table 29: Sub-Type Specific cases of the Acne Vulgaris (AV) in UK (2016-2027)

Table 30: Sex- Specific Cases of the Acne Vulgaris (AV) in UK (2016-2027)

Table 31: Diagnosed Cases of the Acne Vulgaris (AV) in UK (2016-2027)

Table 32: Treatable Cases of the Acne Vulgaris (AV) in UK (2016-2027)

Table 33: Prevalent/Incident Cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Table 34: Sub-Type Specific cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Table 35: Sex- Specific Cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Table 36: Diagnosed Cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Table 37: Treatable Cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Table 38: Marketed Therapies

Table 39: Emerging Therapies

Table 40: Key Cross Competition

Table 41:7MM- Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Table 42:7MM- Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 43:7MM- Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 44: United States-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Table 45: United States-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 46: United States-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 47: Germany-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Table 48: Germany-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 49: Germany-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 50: France-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Table 51: France-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 52: France-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 53: Italy-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Table 54: Italy-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 55: Italy-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 56: Spain-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Table 57: Spain-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 58: Spain-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 59:UK-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Table 60:UK-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 61:UK-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 62: Japan-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Table 63: Japan-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Table 64: Japan-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

List Of Figures, Charts and Diagrams in Acne Vulgaris (AV)- Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Figure 1: Total Prevalent/Incident Cases of the Acne Vulgaris (AV) in 7MM

Figure 2: Total Prevalent/Incident Cases of the Acne Vulgaris (AV) in 7MM by Countries

Figure 3: Prevalent/Incident Cases of the Acne Vulgaris (AV) in United States (2016-2027)

Figure 4: Sub-Type Specific cases of the Acne Vulgaris (AV) in United States (2016-2027)

Figure 5: Sex- Specific Cases of the Acne Vulgaris (AV) in United States (2016-2027)

Figure 6: Diagnosed Cases of the Acne Vulgaris (AV) in United States (2016-2027)

Figure 7: Treatable Cases of the Acne Vulgaris (AV) in United States (2016-2027)

Figure 8: Prevalent/Incident Cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Figure 9: Sub-Type Specific cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Figure 10: Sex- Specific Cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Figure 11: Diagnosed Cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Figure 12: Treatable Cases of the Acne Vulgaris (AV) in Germany (2016-2027)

Figure 13: Prevalent/Incident Cases of the Acne Vulgaris (AV) in France (2016-2027)

Figure 14: Sub-Type Specific cases of the Acne Vulgaris (AV) in France (2016-2027)

Figure 15: Sex- Specific Cases of the Acne Vulgaris (AV) in France (2016-2027)

Figure 16: Diagnosed Cases of the Acne Vulgaris (AV) in France (2016-2027)

Figure 17: Treatable Cases of the Acne Vulgaris (AV) in France (2016-2027)

Figure 18: Prevalent/Incident Cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Figure 19: Sub-Type Specific cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Figure 20: Sex- Specific Cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Figure 21: Diagnosed Cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Figure 22: Treatable Cases of the Acne Vulgaris (AV) in Italy (2016-2027)

Figure 23: Prevalent/Incident Cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Figure 24: Sub-Type Specific cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Figure 25: Sex- Specific Cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Figure 26: Diagnosed Cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Figure 27: Treatable Cases of the Acne Vulgaris (AV) in Spain (2016-2027)

Figure 28: Prevalent/Incident Cases of the Acne Vulgaris (AV) in UK (2016-2027)

Figure 29: Sub-Type Specific cases of the Acne Vulgaris (AV) in UK (2016-2027)

Figure 30: Sex- Specific Cases of the Acne Vulgaris (AV) in UK (2016-2027)

Figure 31: Diagnosed Cases of the Acne Vulgaris (AV) in UK (2016-2027)

Figure 32: Treatable Cases of the Acne Vulgaris (AV) in UK (2016-2027)

Figure 33: Prevalent/Incident Cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Figure 34: Sub-Type Specific cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Figure 35: Sex- Specific Cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Figure 36: Diagnosed Cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Figure 37: Treatable Cases of the Acne Vulgaris (AV) in Japan (2016-2027)

Figure 38: Marketed Therapies

Figure 39: Emerging Therapies

Figure 40: Key Cross Competition

Figure 41: 7MM- Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Figure 42: 7MM- Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 43: 7MM- Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 44: United States-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Figure 45: United States-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 46: United States-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 47: Germany-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Figure 48: Germany-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 49: Germany-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 50: France-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Figure 51: France-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 52: France-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 53: Italy-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Figure 54: Italy-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 55: Italy-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 56: Spain-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Figure 57: Spain-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 58: Spain-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 59:UK-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Figure 60:UK-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 61:UK-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 62: Japan-Market Size of Acne Vulgaris (AV) in USD MM (2016-2027)

Figure 63: Japan-Market Share Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

Figure 64: Japan-Market Sales of Acne Vulgaris (AV) by Therapies in USD MM (2016-2027)

How to Buy...

Acne Vulgaris (AV)- Market Insight, Epidemiology and Market Forecast - 2027 [Report Updated: 14-02-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/201707>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$6250** | Single User Price
- \$12500** | Site License Price
- \$18750** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.